Background and objectives: Previously, we have shown that 9-cis retinoic acid (9-cis RA) stimulates lymphangiogenesis and limits postsurgical lymphedema in animal models when administered via daily intraperitoneal injections. In this study, we investigate whether a single-use depot 9-cis RA drug delivery system (DDS) implanted at the site of lymphatic injury can mitigate the development of lymphedema in a clinically relevant mouse limb model.
| INTRODUCTION
Lymphedema is a disfiguring disease resulting from injury, infection, or congenital malformation of the lymphatic system affecting over 250 million individuals worldwide. 1 The pathogenesis of lymphedema originates from impaired lymphatic transport capacity resulting in the buildup of fluid, protein, and fibroadipose tissue in the interstitial space, causing progressive enlargement of the affected body part.
Depending on the location of the injury, lymphedema can affect the upper extremity, lower extremity, genitalia, abdomen, or head and neck. Primary lymphedema is rare, affecting 1:6000-10 000 live births because of inborn defects of lymphangiogenesis. 2 Secondary lymphedema is more common and results in a significant disease burden, particularly for the cancer patient population. In the US, secondary lymphedema affects over five million cancer survivors and is most often caused by direct lymphatic injury during the resection or irradiation of solid organ tumors, including breast, gynecologic, and lower extremity malignancies. 1 Unfortunately, no curative therapy exists for lymphedema. with high healthcare costs, patient adherence is poor in the longterm. 3 For this reason, advances in the surgical and pharmacologic management of lymphedema have recently garnered scientific interest. New microsurgical procedures, such as vascularized lymph node transfer and lymphaticovenous bypass, aim to redirect obstructed lymphatic flow into the venous circulation to decongest the affected body part. More extreme debulking procedures, which resect subcutaneous and fibroadipose tissue and cover the resulting defect with skin grafts, are used for patients with extensive tissue fibrosis characteristic of end-stage lymphedema. 4 In an effort to explore novel options for lymphedema management, current research efforts include the investigation of pharmacologic agents with pro-lymphangiogenic properties. Several growth factors have already been shown to stimulate lymphangiogenesis in animal models, such as VEGF-C and VEGF-D. [5] [6] [7] [8] However, these drugs have been linked to the promotion of tumor metastasis, making their use relatively contraindicated in patients with a history of cancer, which comprise a significant proportion of patients with lymphedema in the US. [9] [10] [11] A retinoic acid derivative, 9-cis retinoic acid (9-cis RA) has recently been shown to stimulate lymphangiogenesis without promoting tumor metastasis. Landmark studies have revealed significantly increased lymphatic endothelial cell proliferation, migration, and vessel formation when treated with 9-cis RA in vitro. Animal studies have corroborated these findings by demonstrating increased lymphatic vessel density and function in vivo. [12] [13] [14] Importantly, unlike the pro-lymphangiogenic growth factors VEGF-C and VEGF-D, 9-cis RA demonstrates a favorable risk profile in patients with a history of cancer. Moreover, it has already been FDA-approved for Kaposi sarcoma of the skin and chronic hand eczema in the US. Its lack of known associated teratogenicity, unlike other retinoic acid compounds, such as isotretinoin, further makes it a favorable candidate for studies on lymphedema therapy. Previous animal studies have tested 9-cis RA given through daily intraperitoneal injections, a method of drug administration that has poor translatability to future clinical trials because of the painful nature of the injection and the need for daily follow-up. In this study, we aim to investigate the pro-lymphangiogenic effects of 9-cis RA contained within an implantable, single-use pellet for sustained drug delivery in a clinically relevant mouse lymphedema model. The data from this study will help set the stage for the use of a 9-cis RA in future human trials and aid in the development of this promising pharmacologic agent for the prevention of postsurgical lymphedema.
| MATERIALS AND METHODS

| Animals
All experiments were performed in accordance with the statutes from The Guide for the Care and Use of Laboratory Animals 13, 15 Animals were housed in a light-and temperaturecontrolled environment with access to food and water ad libitum.
| Hind limb lymphedema model
A timeline of the experimental methodology is depicted in Figure 1 .
Under isoflurane-inhaled anesthesia, the lymphatic injury protocol was used on all experimental mice to induce hind limb lymphedema.
This consisted of hind limb lymph node dissection followed by adjuvant radiation therapy. Using a dissecting microscope, a circumferential intradermal incision was made around the thigh, after which the ipsilateral inguinal fat pad (containing the inguinal lymph nodes) and the ipsilateral popliteal lymph node were removed, as previously described. 13 
| Postoperative measurements
Before surgery, all animals were sex-, age-, and weight-matched to eliminate confounding variables. Bilateral paw thickness, the primary outcome to assess lymphedema development, was measured weekly using electronic calipers for a total of 6 weeks. Hind limbs were photographed using a Nikon D5000 digital SLR flash camera using fixed distance, focal length, background, and positioning. To account for age-appropriate growth and differences in animal size, paw thickness was normalized for each animal by calculating percent change relative to the unoperated paw using the formula (T o -T u )/ T u × 100, where T o is the thickness of the operated paw and T u is the thickness of the unoperated paw. All measurements were performed in triplicate and statistically analyzed as mean values.
| Indocyanine green lymphography
At postoperative week 6, lymphatic clearance was measured using indocyanine green (ICG) lymphography to compare lymphatic function between the treatment and placebo groups. ICG is a fluorescent dye that, upon activation by a laser light source, displays a signal that can be imaged using near-infrared systems. It has been shown to be superior to lymphoscintigraphy in a clinical setting, with both sensitivity and specificity of 100%. 16 After inducing anesthesia via isoflurane inhalation, a sub-microliter injection system syringe was used to intradermally inject 2 μL of ICG on the plantar aspect of the second and fifth paw digits. ICG lymphography images were recorded using SPY-Q technology (Novadaq Technologies, BC, Canada) at 1, 3, 6, 12, 24, 48, 72, 96, and 144 hours post-injection. 
| Histological assessment
Hind limb tissue harvested at euthanasia was fixed in 10% neutral buffered formalin for 24 hours, decalcified using Surgipath F I G U R E 1 Timeline of the experimental methodology. Starting from day 0 (day of surgery), paw measurements were obtained weekly for a total of 6 weeks. At the final timepoint, animals underwent lymphatic clearance analysis before being euthanized for tissue harve sting. 9-cis RA, 9-cis retinoic acid Decalcifier II solution (Leica Biosystems Inc, Buffalo Grove, IL), embedded in paraffin, and sectioned using 3 to 5 μm tissue thickness.
Hematoxylin and Eosin (H&E) staining of operated mouse paws was performed to document differences in the histological architecture of the soft tissues of the paw between treatment and control groups. Picrosirius red staining of operated mouse paws was performed to detect differences in fibrotic response between the two groups.
Staining was performed by bathing cross-sections in picrosirius red solution (Sigma-Aldrich, St. Louis, MO) for 40 minutes, followed by dehydration and mounting. Collagen deposition was quantified using at least three images per cross-section taken at 20× magnification by measuring percent collagen area (in red) divided by total tissue area within the dermis.
| Immunohistochemical assessment
Formalin-fixed and paraffin-embedded samples of mouse paws were immunostained for LYVE-1 (catalog # NB600-1008; Novus Biologicals, Centennial, CO) according to manufacturer recommendations.
Briefly, sections were deparaffinized, heated in citrate buffer for antigen retrieval, and incubated in primary antibody for LYVE-1
(1:200) at 4°C in 5% bovine serum albumin blocking buffer overnight.
Sections were then incubated in biotinylated secondary antibody (1:200) for 2 hours, followed by incubation with alkaline phosphatase-conjugated streptavidin and diaminobenzidine. To document the differences in lymphatic density, the number and diameter of LYVE-1 positive lymphatic vessels were quantified on ImageJ using at least three images per cross-section taken at 40× magnification. Compared with control animals, animals treated with 9-cis RA showed significantly reduced paw swelling at postoperative week 3 (7% mean difference, P = .04), week 4 (12% mean difference, P = .0002), week 5 (9% mean difference, P = .0005), and week 6 (11% mean difference, P = .0007). Within the treatment group, no significant difference in paw swelling was observed between time points. 9-cis RA, 9-cis retinoic acid by measuring the percentage of picrosirius red-stained dermis divided by total tissue area ( Figure 6A,B) . Picrosirius red staining revealed that the operated paw skin of mice treated with 9-cis RA had a 15% reduction in collagen density compared to animals receiving placebo (P = 0.10), indicating a reduced fibrotic response to lymphedema ( Figure 6G ). Moreover, because epidermal hyperplasia is a common histological finding of skin tissue affected by lymphedema, we quantified epidermal hyperplasia by measuring the thickness of the Malpighian layer in H&E sections of operated mouse paw skin ( Figure 6C,D) . The Malpighian layer consists of the intrinsic stratum spinosum and stratum basale components of the epidermis. This was specifically measured to exclude the stratum corneum from the analysis, as the stratum corneum can be artificially altered by tissue processing and other environmental factors, thus acting as a confounding variable. As shown in Figure 6H , the Malpighian layer was significantly thinner in animals treated with 9cis RA implants compared to control animals (55% mean difference, P = .04), suggesting that 9-cis RA released from implantable pellets prevents epidermal hyperplasia and lymphedema progression. Figure 6J ). Moreover, the pro-lymphangiogenic effects of 9cis RA were specifically observed on lymphatic staining, as animals treated with 9-cis RA DDS had significantly more LYVE-1 positive lymphatic vessels than placebo-treated animals (P = .04), indicating lymphatic endothelial cell proliferation ( Figure 6I ). Thus, 9- node dissection. 17, 18 The extremities are the area most commonly affected by lymphedema. Of the patients with postsurgical lymphedema, approximately 90% have lower extremity lymphedema and 10% have upper extremity lymphedema. 19 The mainstay of lymphedema therapy is achieved through conservative management with variable rates of success, significant healthcare costs, and poor patient adherence. Moreover, no curative therapy exists for established disease, which results in significant fibroadipose tissue deposition causing physical deformity and chronic functional deficits. 
| Statistical analysis
| Sustained release 9-CIS RA maintains lymphatic vessel structure and density after lymphadenectomy
| CONCLUSIONS
In summary, we present a clinically feasible method of drug delivery for the management of postsurgical lymphedema. The clinical F I G U R E 6 Sustained release 9-cis RA decreases epidermal hyperplasia, collagen deposition, and lymphatic vessel size. A, Representative picrosirius red stained cross-section of operated paw skin from a 9-cis RA-treated mouse. Horizontal scale bars represent 100 μm. B, Representative picrosirius red stained cross-section of operated paw skin from a placebo-treated mouse. Note the decrease in collagen deposition in the operated paw skin of mice treated with 9-cis RA DDS pellets. C, Representative H&E stained cross-section of operated paw skin from a 9-cis RA-treated mouse. Horizontal scale bars represent 100 μm, vertical arrows represent Malpighian layer thickness. D, Representative H&E stained cross-section of operated paw skin from a placebo-treated mouse. Note the decrease in hyperkeratosis and acanthosis in the operated paw skin of mice treated with 9-cis RA DDS pellets. E, Representative LYVE-1 stained cross-section of operated paw skin from a 9-cis RA-treated mouse. Horizontal scale bars represent 100 μm, closed arrows indicate lymphatic vessels. F, Representative LYVE-1 stained cross-section of operated paw skin from a placebo-treated mouse. Note the smaller lymphatic vessel diameter in the operated paw skin of mice treated with 9-cis RA DDS pellets. G, Animals receiving 9-cis RA DDS pellets showed a 15% decrease in collagen density per total tissue area compared with animals receiving placebo, indicating a reduced fibrotic response typical of lymphedema (P = .10). H, Animals receiving 9-cis RA DDS pellets showed a 55% decrease in Malpighian layer thickness compared with animals receiving placebo (P = .04), indicating reduced epidermal hyperplasia typical of lymphedema. I, Animals receiving 9-cis RA DDS pellets showed a 104% increase in the number of LYVE-1+ lymphatic vessels compared with animals receiving placebo (P = .04), indicating increased lymphatic density secondary to lymphangiogenesis. J, Animals receiving 9-cis RA DDS pellets showed a 52% decrease in LYVE-1+ lymphatic vessel diameter compared with animals receiving placebo (P = .02), indicating preservation of the normal lymphatic architecture without luminal dilation. 9-cis RA, 9-cis retinoic acid; DDS, drug delivery system; H&E, Hematoxylin and Eosin; LYVE-1, lymphatic vessel endothelial hyaluronan receptor-1 DANESHGARAN ET AL. | 107 applicability of an implantable pellet DDS that results in the sustained local release of the pro-lymphangiogenic drug, 9-cis RA, has significant implications to the field of lymphedema. It allows for the convenient administration of 9-cis RA, which, from a patient and provider perspective, would result in 100% compliance (that is, no missed drug doses), fewer follow-up appointments and decreased treatment costs than the previously-investigated daily intraperitoneal administration of 9-cis RA. Moreover, it would facilitate early disease intervention, thus preventing the establishment of late-stage lymphedema, which is a true clinical challenge to revert and manage.
Although further work is necessary to determine the safety and efficacy of this route of administration in large animals and eventually humans, the data presented here further support 9-cis RA as a safe and effective pharmacologic agent for the treatment of secondary postsurgical lymphedema in humans.
